ADAM15 293T Cell Transient Overexpression Lysate(Denatured)
- Known as:
- ADAM15 293T Cell Transient Overexpression Lysate(Denatured)
- Catalog number:
- H00008751-T01
- Product Quantity:
- 100 uL
- Category:
- -
- Supplier:
- Abno
- Gene target:
- ADAM15 293T Cell Transient Overexpression Lysate(Denatured)
Related genes to: ADAM15 293T Cell Transient Overexpression Lysate(Denatured)
- Gene:
- ADAM15 NIH gene
- Name:
- ADAM metallopeptidase domain 15
- Previous symbol:
- -
- Synonyms:
- MDC15
- Chromosome:
- 1q21.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-12-01
- Date modifiied:
- 2015-08-24
Related products to: ADAM15 293T Cell Transient Overexpression Lysate(Denatured)
Related articles to: ADAM15 293T Cell Transient Overexpression Lysate(Denatured)
- Identifying new drug targets is essential for improving breast cancer survival. The proteome provides a rich source for potential therapeutic targets. This study aimed to identify protein markers and therapeutic targets for breast cancer by using proteome-wide Mendelian randomization (MR). - Source: PubMed
Publication date: 2025/08/04
Cao ZheXuPeng QiyunTan Shenglan - Aqueous humor outflow through the trabecular meshwork (TM) is segmental, demonstrating high flow (HF) and low flow (LF) regions. Here, we investigate transcriptomic differences between flow regions in naïve mouse and non-glaucomatous human TM tissue to better understand intraocular pressure (IOP) regulation. - Source: PubMed
Publication date: 2026/07/24
Wong Cydney ARead A ThomasChrenek MicahLi GuorongStamer W DanielWood Levi BEthier C Ross - A disintegrin and metalloproteinase 15 (ADAM15) is a cell-surface protease with a paradoxical role in cancer development. In this review, we provide a comprehensive overview of the dual functions of ADAM15, highlighting recent mechanisms including exosomal communication, non-coding (nc)RNA regulation (miR-3174, miR-526b-5p, and lncRNA NCK1-AS1), and antiangiogenic metargidin peptide (AMEP), which has completed Phase I trials. We also present a systematic therapeutic strategy matrix covering small molecules, antibodies, RNA therapeutics, proteolysis-targeting chimeras (PROTACs), G-quadruplex stabilizers, and combination therapies, alongside a detailed research gap analysis and actionable future directions. - Source: PubMed
Publication date: 2026/07/21
El-Far AliSong BinghuiFu JunjiangCheng Jingliang - Emerging evidence shows that morning chronotype is associated with a reduced risk of breast cancer, yet biological mechanisms remain unclear. This study aimed to identify circulating proteins that mediate this association. - Source: PubMed
Publication date: 2026/06/20
Luo ShanAi YujieZheng JieWan Eric Yuk FaiYoshiji SatoshiAu Yeung Shiu Lun - Hepatocellular carcinoma (HCC) continues to pose a major health concern for global public health, characterized by pronounced clinical heterogeneity in survival outcomes and therapeutic efficacies. The stromal senescence constitutes a major impediment in constructing robust prognostic models. This study aimed to develop and validate a robust prognostic prediction model to accurately assess the prognostic risk of HCC patients and facilitate personalized precision treatment. - Source: PubMed
Publication date: 2026/05/27
Lu JinZhang ZhenhuaYuan WeiZhang Yingjian